Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Intuitive Surgical, Inc. (ISRG), Medtronic, Inc. (MDT), Stryker Corporation (SYK): Big Growth Opportunities for Three Medical Equipment Makers

Page 1 of 2

Some diseases cannot be cured by traditional drugs but instead require a surgical procedure. This is one of the reasons for constant and increasing demand for medical equipment. The global market for medical equipment is expected to increase at a compound annual growth rate of 7.1% from $307.7 billion in 2012 to $434.4 billion by 2017. In order to monetize this opportunity, the medical equipment manufacturing companies are constantly conducting research and development to create new and efficient equipment.

Medical equipment manufacturers stand to gain from increasing demand. Let’s analyze the growth opportunities for three such companies.

Intuitive Surgical, Inc. (NASDAQ:ISRG)

Japan: a growth opportunity for da Vinci systems

Intuitive Surgical, Inc. (NASDAQ:ISRG) installed 105 da Vinci systems in Japan in the first quarter of 2013. The da Vinci system is a single-site robot, which assists surgeons performing single-incision cancer removals. Da Vinci systems can be used to treat a wide range of cancer conditions including:

  1. Bladder Cancer
  2. Colorectal Cancer
  3. Gynecologic Cancer
  4. Kidney Cancer
  5. Lung Cancer
  6. Prostate Cancer
  7. Throat Cancer

The Japanese Ministry of Health says cancer is the leading cause of death, accounting for 30% of deaths in the country. Every year, around 600,000 Japanese residents are treated for stomach, colorectal, and prostate cancer.

Japan, ranked second, accounts for 10% of global medical technology sales. Japan’s demand creates the opportunity to install 300 da Vinci systems this year. According to the company’s estimate, Japan represents a more than $400 million market opportunity for da Vinci.

Source: Intuitive Surgical

There is also an increase in demand for Intuitive Surgical, Inc. (NASDAQ:ISRG)’s instruments and accessories used with the base da Vinci systems. The instruments and accessories need to be replaced periodically as they have limited life. A simple change of instruments and accessories eases use of the da Vinci systems. Around 2,650 da Vinci systems are now installed globally. The demand for instruments and accessories is directly proportional to the demand of the da Vinci systems. Expected revenue of the instruments and accessories segment for this year is $1 billion and $1.32 billion next year.

Huge market opportunity for renal device

Medtronic, Inc. (NYSE:MDT)’s new renal denervation – or RDN – device, Symplicity, is showing positive results for patients with high blood pressure. Symplicity decreases the production of hormones, which results in lower blood pressure and calms the hyperactive nerves in the kidney. More than 1.2 billion people suffer from high blood pressure across the world with 75 million residing in the U.S. With 10% of patients unresponsive to available drugs, RDN devices have an opportunity to grow. The overall renal denervation market is expected to increase from $17 million in 2011 to $561 million by 2015.

Source: Medgadget

The pacemakers and defibrillators segment of Medtronic, Inc. (NYSE:MDT) observed an increase in demand for its second-generation MRI-safe pacemaker, Advisa. A pacemaker is an electronic device implanted in the chest or abdomen of cardiac patients. It controls abnormal heartbeats and increases slow heartbeats. Due to increasing heart problems worldwide, there is a huge demand for its pacemakers and second-generation MRI-safe pacemaker, Advisa. The global cardiac pacemakers market is expected to increase at a compound annual growth rate of 11% from 2009 and reach $5.1 billion by 2015.

Source: Medgadget

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!